Abiopharma

IQVIA Reports Third-Quarter 2025 Results

Lifecore and PolyPeptide Announce Collaboration Intended to Offer End-to-End Peptide Manufacturing Solution for U.S. Market

Bioventus to Report Third Quarter of Fiscal Year 2025 Financial Results on November 4, 2025

Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025

Natera Reports Strong Advanced Adenoma Data from Prospective PROCEED-CRC Trial, Demonstrating 22.5% Sensitivity and 91.5% Specificity

Ocular Therapeutix™ to Report Third Quarter 2025 Financial Results on November 4, 2025

Castle Biosciences to Participate in Upcoming Investor Conferences

Alkermes plc Reports Third Quarter 2025 Financial Results

Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch

Merck Announces KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Met Primary Endpoint of Disease-Free Survival (DFS) in Certain Patients With Clear Cell Renal Cell Carcinoma (RCC) Following Nephrectomy